Similarly, genetically determined circulating levels of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) were nominally associated with the risk AML (OR=1.27, 95% CI: 1.06-1.52, P=0.011), colon cancer (OR=1.07, 95% CI: 1.01-1.13, P=0.021), CLL (OR=1.27, 95% CI: 1.06-1.52, P=0.011), lung cancer (OR=0.93, 95% CI: 0.87-0.99, P=0.034), non-Hodgkin lymphoma (OR=0.91, 95% CI: 0.84-0.99, P=0.034), and rectal cancer (OR=1.08, 95% CI: 1.01-1.15, P=0.032). The gene discussed is TNFSF10; the disease is non-Hodgkin lymphoma.